Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Not yet recruiting 7Unknown 6Recruiting 6Active not recruiting 6Completed 5Terminated 1Available 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5Solid Advanced Tumor 1Lung Neoplasms 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × ensartinib × Clear all
NCT06563999 2026-04-21

NUMER

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07354061 2026-04-01

TD-ENSEMBLE

Tang-Du Hospital

Phase 1/2 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07448116 2026-03-04

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Betta Pharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
164 enrolled

Solid Advanced Tumor

NCT05341583 2024-08-23

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 3 Recruiting
202 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05241028 2023-10-10

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Hebei Medical University Fourth Hospital

Phase 2 Recruiting
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05498064 2022-08-11

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Peking Union Medical College Hospital

Recruiting
490 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡